199 related articles for article (PubMed ID: 26107212)
41. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
42. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
[TBL] [Abstract][Full Text] [Related]
43. Outcome of modified St Jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey.
Koc A; Aycicek A; Ozdemir ZC; Soker M; Varma M
J Pediatr Hematol Oncol; 2013 Jan; 35(1):36-41. PubMed ID: 23138117
[TBL] [Abstract][Full Text] [Related]
44. [Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol].
Ruan YS; Wu XD; Feng XQ; He YL; Zhang YM; Pei FY; Li CF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Apr; 17(4):327-31. PubMed ID: 25919549
[TBL] [Abstract][Full Text] [Related]
45. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia.
Tsurusawa M; Shimomura Y; Asami K; Kikuta A; Watanabe A; Horikoshi Y; Matsushita T; Kanegane H; Ohta S; Iwai A; Mugishima H; Koizumi S;
Leukemia; 2010 Feb; 24(2):335-44. PubMed ID: 20016539
[TBL] [Abstract][Full Text] [Related]
46. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
47. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
49. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
50. Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: A national population-based study.
White VM; Skaczkowski G; Pinkerton R; Coory M; Osborn M; Bibby H; Nicholls W; Orme LM; Conyers R; Phillips MB; Harrup R; Walker R; Thompson K; Anazodo A
Pediatr Blood Cancer; 2018 Nov; 65(11):e27349. PubMed ID: 30039912
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
Balduzzi A; Valsecchi MG; Uderzo C; De Lorenzo P; Klingebiel T; Peters C; Stary J; Felice MS; Magyarosy E; Conter V; Reiter A; Messina C; Gadner H; Schrappe M
Lancet; 2005 Aug 20-26; 366(9486):635-42. PubMed ID: 16112299
[TBL] [Abstract][Full Text] [Related]
52. Prognosis and outcome of relapsed acute lymphoblastic leukemia: a Hong Kong Pediatric Hematology and Oncology Study Group report.
Leung AW; Vincent L; Chiang AK; Lee AC; Cheng FW; Cheuk DK; Luk CW; Ling SC; Li CK
Pediatr Blood Cancer; 2012 Sep; 59(3):454-60. PubMed ID: 22610685
[TBL] [Abstract][Full Text] [Related]
53. [Testicular recurrence of acute lymphoblastic leukemia in children treated by BFM 81 83 protocol. Report of the Polish Group for the Treatment of Leukemia and Other Lymphatic Diseases in Children].
Koehler M; Bubała H; Daszkiewicz P; Newecka-Samól T; Rodziewicz B; Rytlewska M; Skrobowska A; Sońta-Jakimczyk D; Trendowska D
Pol Tyg Lek; 1988 Dec; 43(50):1615-8. PubMed ID: 3256802
[No Abstract] [Full Text] [Related]
54. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.
Navarrete M; Rossi E; Brivio E; Carrillo JM; Bonilla M; Vasquez R; Peña A; Fu L; Martinez R; Espinoza CM; Lacayo LF; Rodriguez H; Batista R; Barr R; Howard SC; Ribeiro RC; Masera G; Biondi A; Conter V; Valsecchi MG
Pediatr Blood Cancer; 2014 May; 61(5):803-9. PubMed ID: 24376115
[TBL] [Abstract][Full Text] [Related]
55. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area.
Howard SC; Pedrosa M; Lins M; Pedrosa A; Pui CH; Ribeiro RC; Pedrosa F
JAMA; 2004 May; 291(20):2471-5. PubMed ID: 15161898
[TBL] [Abstract][Full Text] [Related]
56. BFM group treatment results in relapsed childhood acute lymphoblastic leukemia.
Henze G; Fengler R; Hartmann R; Niethammer D; Schellong G; Riehm H
Haematol Blood Transfus; 1990; 33():619-26. PubMed ID: 2182452
[No Abstract] [Full Text] [Related]
57. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.
Sallan SE; Gelber RD; Kimball V; Donnelly M; Cohen HJ
Haematol Blood Transfus; 1990; 33():459-66. PubMed ID: 2182437
[TBL] [Abstract][Full Text] [Related]
58. [Treatment of children with recurrent acute lymphoblastic leukemia].
Sotnikova NI
Pediatriia; 1989; (4):62-5. PubMed ID: 2734065
[No Abstract] [Full Text] [Related]
59. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
[TBL] [Abstract][Full Text] [Related]
60. [Childhood acute lymphoblastic leukemia in Norway 1992-2000].
Kolmannskog S; Flaegstad T; Helgestad J; Hellebostad M; Zeller B; Glomstein A
Tidsskr Nor Laegeforen; 2007 May; 127(11):1493-5. PubMed ID: 17551551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
